Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftriaxone–tazobactam (6:1) vs (3:1) in acute lower respiratory and urinary tract infections
CTR20132852Phase 2Active
- Sponsor
- Xiangbei Welman Pharmaceuticals
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ceftriaxone + tazobactam in pulmonary infection, community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), acute bronchitis, chronic bronchitis (CB), sponsored by Xiangbei Welman Pharmaceuticals. Started Mar 2014; status: active.
02
Drugs
ceftriaxone + tazobactam
03
Conditions
pulmonary infectioncommunity-acquired pneumonia (CAP)hospital-acquired pneumonia (HAP)acute bronchitischronic bronchitis (CB)
Beyond the preview
Go deeper on CTR20132852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132852.